While Japan has now granted its first emergency approval to Shionogi’s COVID-19 pill Xocova (ensitrelvir), the drug failed to win a unanimous vote by advisory panels, with skepticism lingering over its actual efficacy. To prep for the next emergency, which…
HOME > BUSINESS
BUSINESS
- Santen Reports Steady 5.3% Increase in Sales in Domestic, Overseas Markets in Apr-Sep
November 2, 2011
- Eisai President Says Japan, China to Become Key Battlefields for Aricept
November 2, 2011
- Bayer Yakuhin to Reorganize Structure, Offer Early Retirement Program to 150
November 2, 2011
- AstraZeneca’s 9-Month Global Sales Fell Due to Competition with Generics
November 2, 2011
- Profits Show Double-Digit Drop Due to Increased R&D Costs: Torii
November 2, 2011
- Daiichi Sankyo Suspends PII Trials in US, Europe for Post-Surgery VTE Prevention
November 2, 2011
- Shionogi Aiming for US Launch of Vaginal Atrophy Treatment Ospemifene in 2013
November 2, 2011
- Marketing of Imusera, Telavic to Be Limited to Specialists at First: MTPC
November 2, 2011
- Daiichi Sankyo Reports Decreases in Sales, Profits in Apr-Sept Term by Slump of Ranbaxy, Return of Marketing Rights
November 1, 2011
- MTPC: Profits Down but Remicade, Generics Show Steady Growth in Apr-Sept
November 1, 2011
- DSP to Boost Domestic CNS Business for Early Maximization of Lonasen
November 1, 2011
- Shionogi’s Strength in Japan Weakened by Slack US Results, Overall Sales Down 13.5% in Apr-Sept
November 1, 2011
- Sharp Decrease in Profits due to Declines in License Revenues: JCR’s Half year Financial Report
November 1, 2011
- Zeria Upwardly Revises Profits forecasts for 1st Half of FY2012
November 1, 2011
- Mochida: Epadel, Lexapro Drive Growth in 1st-Half Sales and Profits
November 1, 2011
- DSP: Strong Yen Contributes to 5.6% Decline in Sales
November 1, 2011
- Further Deterioration in Sales Prices Unlikely in 2nd Half: President Watanabe of Mediceo
November 1, 2011
- Three Top Dispensing Pharmacy Chains Report 50% Growth in Operating Profits
November 1, 2011
- ASKA Downwardly Revises Sales Forecast Due to Effects of Quake
October 31, 2011
- Astellas Upwardly Revises Business Forecasts Driven by Vesicare
October 31, 2011
ページ
As the year 2022 draws to a close, what are managers thinking at the world’s leading pharmaceutical companies and medical device companies? We surveyed 86 managers at these companies to find out what’s on their minds.For many managers, a common…
A Japanese reimbursement policy panel on November 16 saw a continued scuffle between members representing healthcare providers and payers over…
Deloitte Tohmatsu Consulting proposed three drug pricing schemes designed to trigger the consolidation of generic makers on October 27, offering…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…